Cellectis S.A. (NASDAQ:CLLS) Holdings Decreased by Baillie Gifford & Co.

Baillie Gifford & Co. cut its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 1.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 693,939 shares of the biotechnology company’s stock after selling 13,691 shares during the quarter. Baillie Gifford & Co. owned 1.25% of Cellectis worth $1,485,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the period. First Affirmative Financial Network bought a new position in Cellectis in the third quarter worth about $45,000. XTX Topco Ltd bought a new position in Cellectis in the second quarter worth about $29,000. Finally, Principal Financial Group Inc. boosted its stake in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Barclays cut their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. StockNews.com assumed coverage on Cellectis in a research note on Wednesday. They issued a “sell” rating on the stock.

Cellectis Stock Performance

CLLS opened at $1.98 on Thursday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $2.02 and its 200-day moving average is $2.25. The stock has a market cap of $110.06 million, a PE ratio of -1.52 and a beta of 3.10. Cellectis S.A. has a twelve month low of $1.70 and a twelve month high of $3.77.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same period in the previous year, the firm earned ($0.31) EPS. On average, analysts predict that Cellectis S.A. will post -0.46 earnings per share for the current year.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.